Last weekend, I travelled to Chicago for the annual conference of the American Society of Clinical Oncologists— the annual event where major breakthroughs in cancer care are announced.
Just about everyone seems to agree that the runaway success story of ASCO this year is AstraZeneca, with plenary sessions for the sixth year in a row and
CAR-T treatments emerged as a major success for the pharma industry when first approved in 2017, but this has been muddied by concerns over secondary malignancies.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
